HC Wainwright Issues Optimistic Estimate for DWTX Earnings

Dogwood Therapeutics, Inc (NASDAQ:DWTX) – Investment analysts at HC Wainwright increased their Q1 2026 EPS estimates for shares of Dogwood Therapeutics in a research report issued on Thursday, March 19th. HC Wainwright analyst S. Lee now anticipates that the company will earn ($0.30) per share for the quarter, up from their prior estimate of ($0.49). HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Dogwood Therapeutics’ current full-year earnings is ($6.43) per share. HC Wainwright also issued estimates for Dogwood Therapeutics’ Q2 2026 earnings at ($0.32) EPS, Q3 2026 earnings at ($0.34) EPS, Q4 2026 earnings at ($0.37) EPS, FY2026 earnings at ($1.33) EPS, FY2027 earnings at ($1.62) EPS, FY2028 earnings at ($1.71) EPS and FY2029 earnings at $0.72 EPS.

DWTX has been the subject of several other reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Dogwood Therapeutics in a research report on Monday, December 22nd. Wall Street Zen cut Dogwood Therapeutics to a “strong sell” rating in a report on Saturday, December 13th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $12.00.

Dogwood Therapeutics Price Performance

NASDAQ:DWTX opened at $3.00 on Monday. Dogwood Therapeutics has a 1 year low of $2.60 and a 1 year high of $9.50. The stock’s fifty day moving average price is $2.95 and its two-hundred day moving average price is $4.66. The company has a market cap of $100.21 million, a P/E ratio of -0.16 and a beta of 1.90.

Dogwood Therapeutics (NASDAQ:DWTX) last released its quarterly earnings data on Wednesday, March 18th. The company reported ($0.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.22) by $0.96.

Institutional Trading of Dogwood Therapeutics

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP purchased a new stake in Dogwood Therapeutics, Inc (NASDAQ:DWTX) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned 0.51% of Dogwood Therapeutics at the end of the most recent reporting period. Institutional investors own 9.05% of the company’s stock.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics is a clinical‐stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high‐throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.